Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity

Blood (2013) 122 (21): 1447.

https://doi.org/10.1182/blood.V122.21.1447.1447

Published: 2013

Journal Articles

Acute Myeloid Leukemia: Longterm Outcome Predicted by Age and Genetic Groups

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Utz Krug, Claudia Haferlach, MD, Susanne Schnittger, PhD, Matthias Stelljes, MD, Gerda Silling, MD, Peter Staib, MD, Andreas Grueneisen, MD, Albrecht Reichle, Leopold Balleisen, MD, Hartmut Eimermacher, MD, Aristoteles Giagounidis, MD, Herbert Rasche, MD, Eva Lengfelder, MD, Cristina Sauerland, MSc, Achim Heinecke, PhD, Bernhard Josef Woermann, MD, Wolfgang Hiddemann, MD, PhD

Blood (2012) 120 (21): 1509.

https://doi.org/10.1182/blood.V120.21.1509.1509

Published: 2012

Journal Articles

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

Blood (2011) 118 (21): 2773.

https://doi.org/10.1182/blood.V118.21.2773.2773

Published: 2011

Journal Articles

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

Blood (2009) 114 (22): 485.

https://doi.org/10.1182/blood.V114.22.485.485

Published: 2009

Journal Articles

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

Blood (2008) 112 (11): 2599.

https://doi.org/10.1182/blood.V112.11.2599.2599

Published: 2008

Journal Articles

The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

Horst Mueller, Lucia Nogova, Dennis A Eichenauer, Teresa Halbsguth, Hiltrud Nisters-Backes, Thomas Schober, Hartmut Eimermacher, Peter Borchmann, Michael Fuchs, Andreas Engert, Andreas Josting

Blood (2008) 112 (11): 2600.

https://doi.org/10.1182/blood.V112.11.2600.2600

Published: 2008

Journal Articles

The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial

Eva Hoster, Michael Unterhalt, PhD, Bernhard Wörmann, Ulrich Dührsen, Bernd Metzner, Hartmut Eimermacher, Andreas Neubauer, Hannes Wandt, Hjalmar Steinhauer, Sonja Martin, Else Heidemann, Ali Aldaoud, Wolfgang Hiddemann, Martin Dreyling

Blood (2008) 112 (11): 3049.

https://doi.org/10.1182/blood.V112.11.3049.3049

Published: 2008

Journal Articles

Older Age Is An Independent Risk Factor in AML

Blood (2008) 112 (11): 555.

https://doi.org/10.1182/blood.V112.11.555.555

Published: 2008

Journal Articles

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Blood (2008) 111 (2): 558–565.

https://doi.org/10.1182/blood-2007-06-095331

Published: 2008

Includes: Supplemental data

Journal Articles

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study.

Michael Lübbert, MD, Björn Rüter, MD, Rainer Claus, MD, Mathias Schmid, MD, Ulrich Germing, MD, Hartmut Eimermacher, MD, Arnold Ganser, MD, Uwe Platzbecker, MD, Oliver Galm, MD, Wolfram Brugger, MD, Gerhard Heil, MD, Pierre W. Wijermans, MD, Dietmar Pfeifer, PhD, Claudia Schmoor, PhD, Hartmut Döhner, MD

Blood (2007) 110 (11): 300.

https://doi.org/10.1182/blood.V110.11.300.300

Published: 2007

Journal Articles

Final Analysis of Phase II Study of CHOP/CHOEP-14 Followed by Consolidation with Alemtuzumab in Untreated Aggressive T-Cell Lymphomas (DSHNHL 2003–1).

Claudia Binder, Marita Ziepert, Dipl., Math., Markus Loeffler, Michael Pfreundschuh, Norbert Schmitz, Ulrich Duehrsen, Hartmut Eimermacher, A. Haas, A. Aldoud, Lorenz H. Truemper

Blood (2007) 110 (11): 3431.

https://doi.org/10.1182/blood.V110.11.3431.3431

Published: 2007

Journal Articles

Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Blood (2007) 110 (11): 788.

https://doi.org/10.1182/blood.V110.11.788.788

Published: 2007

Journal Articles

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Blood (2007) 109 (11): 4686–4692.

https://doi.org/10.1182/blood-2006-11-055186

Published: 2007

Includes: Supplemental data

Journal Articles

Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Viola Poeschel, MD, Maike Nickelsen, M.D., Mathias Hanel, M.D., Stephan Kremers, M.D., Swen Wessendorf, M.D., Hartmut Eimermacher, M.D., Norma Peter, M.D., Michael Wenger, M.D., Marcel Reiser, M.D., Norbert Schmitz, M.D., Michael Pfreundschuh, M.D.

Blood (2006) 108 (11): 2738.

https://doi.org/10.1182/blood.V108.11.2738.2738

Published: 2006

Journal Articles

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Blood (2005) 106 (12): 3725–3732.

https://doi.org/10.1182/blood-2005-01-0016

Published: 2005

Journal Articles

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.

Michael Lübbert, Björn Rüter, Mathias Schmid, Sabine Knipp, Ulrich Germing, Christiane Dobbelstein, Hartmut Eimermacher, Barbara Deschler, Rainer Claus, Richard Schlenk, Arnold Ganser, Hartmut Döhner, Claudia Schmoor, Hartmut Henß

Blood (2005) 106 (11): 1852.

https://doi.org/10.1182/blood.V106.11.1852.1852

Published: 2005

Journal Articles

The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG).

Wolfgang Hiddemann, MD, PhD, Roswitha Forstpointner, MD, Michael Kneba, MD, PhD, Norbert Schmitz, MD, PhD, Rudolf Schmits, MD, PhD, Bernd Metzner, MD, Marcel Reiser, MD, Eva Lengfelder, MD, PhD, Bernhard Woermann, MD, PhD, Hariett Harder, MD, Susanna Hegewisch-Becker, MD, PhD, Wolfgang Berdel, MD, PhD, Georg Hess, MD, Hartmut Eimermacher, MD, Ali Aldaoud, MD, Manfred Planker, MD, Reza Parwaresch, MD, PhD, Martin Dreyling, MD, PhD, Michael Unterhalt, MD

Blood (2004) 104 (11): 161.

https://doi.org/10.1182/blood.V104.11.161.161

Published: 2004

Journal Articles

Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Christian Buske, MD, PhD, Martin H. Dreyling, MD, PhD, Hartmut Eimermacher, MD, Hans-Peter Boeck, MD, Michael Pfreundschuh, MD, PhD, Bernd Metzner, MD, Roland Fuchs, MD, PhD, Bernhard Woermann, MD, PhD, Lorenz H. Truemper, MD, PhD, Georg Hess, MD, Hannes Wandt, MD, PhD, Wolf-Dieter Ludwig, MD, PhD, Ernst-Dietrich Kreuser, MD, PhD, Joerg Schimke, MD, H.-J. Weh, MD, PhD, Stephan Schmitz, MD, PhD, W. Schmiegel, MD, PhD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, PhD

Blood (2004) 104 (11): 162.

https://doi.org/10.1182/blood.V104.11.162.162

Published: 2004

Journal Articles

Prognostic Impact of Cytogenetics and Early Response and Efficacy of Sequential High-Dose AraC and Idarubicin (S-HAI) in Patients with Refractory and Relapsed Acute Myeloid Leukemia (AML): Results of a Prospective Study.

Blood (2004) 104 (11): 871.

https://doi.org/10.1182/blood.V104.11.871.871

Published: 2004

Journal Articles

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

Michael Pfreundschuh, Lorenz Trümper, Marita Kloess, Rudolf Schmits, Alfred C. Feller, Christian Rübe, Christian Rudolph, Marcel Reiser, Dieter K. Hossfeld, Hartmut Eimermacher, Dirk Hasenclever, Norbert Schmitz, Markus Loeffler, the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

Blood (2004) 104 (3): 634–641.

https://doi.org/10.1182/blood-2003-06-2095

Published: 2004

NARROW

Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity

Acute Myeloid Leukemia: Longterm Outcome Predicted by Age and Genetic Groups

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial

Older Age Is An Independent Risk Factor in AML

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study.

Final Analysis of Phase II Study of CHOP/CHOEP-14 Followed by Consolidation with Alemtuzumab in Untreated Aggressive T-Cell Lymphomas (DSHNHL 2003–1).

Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.

The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG).

Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Prognostic Impact of Cytogenetics and Early Response and Efficacy of Sequential High-Dose AraC and Idarubicin (S-HAI) in Patients with Refractory and Relapsed Acute Myeloid Leukemia (AML): Results of a Prospective Study.

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only